Blog Posts - Post Transplant



ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure  No need seen to alter existing transplantation medication regimens Saturday, April 25, 2015 10:00 am EDT...
by Hepatitis C Research and News on Apr 25, 2015

Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease

-- High Cure Rates in More Than 600 Genotype 1 and 4 Patients With Limited or No Approved Treatment Options -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 23, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 clinic...
by Hepatitis C Research and News on Apr 23, 2015

Combination therapy offers quicker, less toxic eradication of hep C in liver transplant patients

PUBLIC RELEASE DATE: 9-Nov-2014 Contact: Paul Scotti scotti.paul@mayo.edu 904-953-0199 Mayo Clinic JACKSONVILLE, Fla. -- All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplan...


Trending Topics

Close